What it's for (Indications)
- Dorzolamide + timolol ophthalmic solution is specifically indicated for the reduction of elevated intraocular pressure (IOP) in patients diagnosed with open-angle glaucoma or ocular hypertension.
- This fixed-combination medication is particularly appropriate for individuals who require concomitant therapy because they are insufficiently responsive to topical beta-adrenergic receptor blocking agents alone, or when the treating ophthalmologist determines that combination therapy is clinically beneficial.
- The primary goal is to prevent optic nerve damage and subsequent vision loss associated with chronically elevated IOP, thereby preserving visual function over the long term.
- This therapeutic approach is a critical component of managing these progressive ocular conditions, aiming to achieve target IOP levels that minimize the risk of disease progression and maintain the patient's quality of life through vision preservation.
- It serves as a valuable option when monotherapy is no longer adequate or when specific patient profiles warrant a dual-mechanism approach to IOP reduction.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage for dorzolamide + timolol ophthalmic solution is one drop instilled into the conjunctival sac of the affected eye(s) twice daily, typically administered in the morning and evening, with approximately 12 hours between doses. For optimal efficacy and to minimize systemic absorption and potential systemic side effects, patients should be instructed on proper instillation technique. This includes tilting the head back, gently pulling down the lower eyelid to create a small pouch, instilling the drop, and then applying gentle pressure to the nasolacrimal duct (corner of the eye near the nose) immediately after instillation for at least one minute. This technique helps to reduce systemic exposure. If multiple topical ophthalmic medications are being used, they should be administered at least five minutes apart to prevent dilution and ensure optimal absorption of each drug. Patients should not touch the dropper tip to any surface (e.g., eye, fingers, clothing) to avoid contamination of the solution. Adherence to the prescribed dosage and regimen is crucial, and any alterations in frequency or duration of use should only be made under the direct supervision and advice of a qualified ophthalmologist, as incorrect use can impact treatment effectiveness and safety, potentially leading to inadequate IOP control or increased adverse reactions. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects associated with dorzolamide + timolol ophthalmic solution include ocular burning and stinging, taste perversion (dysgeusia), and conjunctival hyperemia (redness).
- Other frequently observed ocular adverse reactions may encompass blurred vision, itchy eyes, dry eyes, superficial punctate keratitis (inflammation of the cornea), corneal erosion, foreign body sensation, and photophobia (light sensitivity).
- Systemic side effects, though generally less common due to topical administration, can occur due to systemic absorption of both components.
- These may include bradycardia (slow heart rate), arrhythmia, dyspnea (shortness of breath), bronchospasm (especially in susceptible individuals with respiratory conditions like asthma), headache, fatigue, nausea, and depression.
- Due to the dorzolamide component, which is a sulfonamide, allergic reactions such as rash, urticaria, and angioedema, though rare, are possible.
- Serious systemic adverse reactions, such as severe respiratory or cardiac events, while infrequent, necessitate immediate medical attention.
- Patients should promptly report any persistent, worsening, or new adverse effects to their healthcare provider for thorough evaluation and appropriate management, ensuring patient safety and treatment continuity.
Serious Warnings
- Black Box Warning: None
- Dorzolamide + timolol ophthalmic solution carries significant warnings due to the potential for systemic absorption of its active components.
- It is strictly contraindicated in patients with bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease (COPD) due to the timolol component, which is a non-selective beta-blocker and can precipitate severe bronchospasm.
- Similarly, it is contraindicated in patients with sinus bradycardia, second or third-degree atrioventricular block, overt cardiac failure, or cardiogenic shock, as timolol can exacerbate these cardiac conditions.
- Caution is advised in patients with diabetes mellitus, as beta-blockers may mask symptoms of acute hypoglycemia.
- The dorzolamide component is a sulfonamide derivative; thus, patients with a history of sulfonamide hypersensitivity may experience allergic reactions, including severe mucocutaneous reactions such as Stevens-Johnson syndrome, although rare.
- Use with caution in patients with severe renal impairment due to the renal excretion of dorzolamide and the potential for increased systemic drug exposure.
- Patients wearing soft contact lenses should remove them prior to instillation and wait at least 15 minutes before reinserting, as the preservative (benzalkonium chloride) can be absorbed by the lenses and cause irritation or discoloration.
- Concomitant use with oral carbonic anhydrase inhibitors or other topical beta-blockers is generally not recommended due to potential additive systemic effects and increased risk of adverse reactions.
- Patients should be monitored for signs of systemic beta-blockade (e.
- g.
- , bradycardia, hypotension) and metabolic acidosis.
- Any sudden changes in vision or signs of allergic reaction warrant immediate medical consultation.
How it Works (Mechanism of Action)
Dorzolamide + timolol ophthalmic solution lowers elevated intraocular pressure (IOP) through a synergistic mechanism involving two distinct pharmacological agents, each targeting different aspects of aqueous humor dynamics. Dorzolamide, a topical carbonic anhydrase inhibitor (CAI), acts by selectively inhibiting the enzyme carbonic anhydrase, which is abundant in the ciliary processes of the eye. This inhibition leads to a significant reduction in the formation of bicarbonate ions within the ciliary epithelium. Subsequently, this decreases sodium and fluid transport across the ciliary epithelium, thereby diminishing the rate of aqueous humor secretion into the posterior chamber of the eye. Timolol, a non-selective beta-adrenergic receptor blocking agent, primarily reduces IOP by decreasing the production of aqueous humor. While its precise cellular mechanism on aqueous humor formation is not fully elucidated, it is believed to involve the blockade of beta-receptors (specifically beta-1 and beta-2 receptors) in the ciliary epithelium. These receptors are thought to play a role in regulating the active secretory processes that contribute to aqueous humor production. Timolol also contributes to lowering IOP through a minor increase in aqueous outflow. The combination of these two agents provides an additive effect on IOP reduction because they operate through distinct yet complementary pathways to reduce aqueous humor production, leading to a more pronounced and sustained pressure-lowering effect than either agent used alone, offering a comprehensive approach to managing ocular hypertension and open-angle glaucoma.
Commercial Brands (Alternatives)
No other brands found for this formula.